The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
Active, not recruiting · NCT06958939 · Registry updated 2026-05-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis | Myasthenia Gravis, Generalized, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Active, not recruiting | Phase 1 | 2026-05-27 | NCT06958939 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hebei Senlang Biotechnology Co., LTD | 3 |
| Ting Chang, MD | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The Second Affiliated Hospital of Air Force Medical University | Xi'an | China | 5 |